Azar: New HHS guidance aimed at curbing drug companies’ ‘abusive behavior’ in Medicaid

HHS Secretary Alex Azar spoke at ALEC's conference on Thursday. (ALEC)

HHS has issued guidance aimed at blocking drug companies from manipulating a loophole in Medicaid’s payment policies that they can use to avoid paying out full rebates for certain medications. 

When a drug manufacturer releases a “line extension” for a medication—for example, releasing an extended release version of a drug they already make—they can reset the price used to calculate the rebates they must pay.

In a letter (PDF) to states from the Centers for Medicare & Medicaid Services, the agency outlines the complex math that Department of Health and Human Services Secretary Alex Azar says will curb “abusive behavior” in Medicaid by drug companies. 

Conference

2019 Drug Pricing and Reimbursement Stakeholder Summit

Given federal and state pricing requirements arising, press releases from industry leading pharma companies, and the new Drug Transparency Act, it is important to stay ahead of news headlines and anticipated requirements in order to hit company profit targets, maintain value to patients and promote strong, multi-beneficial relationships with manufacturers, providers, payers, and all other stakeholders within the pricing landscape. This conference will provide a platform to encourage a dialogue among such stakeholders in the pricing and reimbursement space so that they can receive a current state of the union regarding regulatory changes while providing actionable insights in anticipation of the future.

Azar announced the guidance’s release in a speech at the American Legislative Exchange Council’s conference on Thursday, though the change was mandated by Congress in its bipartisan spending plan passed earlier this year

RELATED: Medicare Part D spending spikes 77% even with prescriptions down 17% 

“Starting today, we’ve made clear that manufacturers must pay the full amount of rebates that they owe under the law,” Azar said. 

The change—a “technical correction,” according to analysis from The Commonwealth Fund—could lead to significant savings in Medicaid drug spending. The Congressional Budget Office estimates the adjustment could save Medicaid $6.5 billion in drug costs over the next decade. 

In a statement, CMS Administrator Seema Verma said that change ensures that that Medicaid program continues to protect the country’s “most vulnerable citizens.” 

“As part of President Trump and Secretary Azar’s commitment to lowering the cost of prescription drugs, CMS is working with states and manufacturers to ensure that Medicaid receives the full amount of drug rebates that are owed,” Verma said. “We want to make the rules abundantly clear to ensure that manufacturers are not gaming the system.” 

RELATED: HHS Secretary Alex Azar’s reform mantra—‘common sense’ 

In his speech, Azar also said that HHS is committed to providing greater flexibility and options to states as part of its varied health reform efforts. States can rethink how they regulate certificates of need or clinical scope of practice to encourage greater competition and choice for patients. 

Regulations such as these, he said, are examples of how the government can stand in the way of beneficial change. 

“I would urge all of you to take a look at how state and local regulations can be impeding healthcare competition, raising costs for patients and depriving them of choices,” Azar said. 

Suggested Articles

Health insurers’ financial performance is on a continuing upward trend, but political and legal risks could pose a threat to that growth.

Senate lawmakers released a draft package of legislation Thursday aimed at curbing health care costs they said they believe they can pass on a bipartisan basis…

Attorneys general seeking to defend the ACA argue that their opponents—including the DOJ—have poor legal standing to challenge the law.